website templates

Driven by physical principles

Wren is advancing an entirely novel approach to address protein misfolding diseases, based on more than a decade of research from its scientific founders

News

On January 22, 2019, Wren announced an £18 million Series A financing from an international syndicate led by The Baupost Group with participation from LifeForce Capital and a number of private investors. 


About

Wren Therapeutics, founded in 2016, is a spin-off company from the University of Cambridge (UK) and Lund University (Sweden). The company is based at the University of Cambridge, in the recently opened Chemistry of Health Centre, and is focused on drug discovery and development for protein misfolding diseases.

The scientific founders include:

  • Sir Chris Dobson FRS FMedSci, John Humphrey Plummer Professor of Chemical and Structural Biology at the University of Cambridge and Master of St John’s College, Cambridge, and Vice-Chairman of the Board of Wren
  • Michele Vendruscolo, Professor of Biophysics at the University of Cambridge, and Chief Scientific Officer of Wren
  • Samuel Cohen, Entrepreneur-in-Residence at St John's College, University of Cambridge, and Chief Executive Officer of Wren
  • Tuomas Knowles, Professor of Chemistry and Physics at the University of Cambridge
  • Sara Linse, Professor of Molecular Protein Science and Physical Chemistry at Lund University and Member of the Nobel Prize Committee for Chemistry
  • Johnny Habchi, Borysiewicz Biomedical Science Fellow at the University of Cambridge, and Head of Research at Wren

Science

About Protein Misfolding Diseases

Wren is focused on drug discovery and development for protein misfolding diseases. Alzheimer's and Parkinson's diseases are widely known examples of this group of medical disorders, but others include type-2 diabetes and many rare diseases amongst the more than 50 in total.

Protein misfolding diseases are one of the most critical global healthcare challenges of the 21st century. However, current strategies - in particular those driven by traditional drug discovery and biological approaches - have proven, at least to date, to be ineffective.

Wren's Proprietary Approach

Wren’s approach is built on concepts from the physical sciences and is based on more than a decade of research focused on the chemical kinetics of the protein misfolding process.

These advances make it possible to map, and selectively modulate, the complex and non-linear chemical kinetic networks associated with misfolding proteins and disease, creating a predictive and quantitatively driven platform that has the potential to radically advance drug discovery for this class of diseases.

Wren is using its unique approach to develop a broad pipeline of small molecule and antibody therapeutics, as well as diagnostics, spanning neurology, ophthalmology and metabolic diseases.

Contact

For all enquiries please send a message to contact@wrentherapeutics.com

Company number 10054518. Registered address: Clarendon House, Clarendon Road, Cambridge CB2 8FH, UK.
© Copyright 2019 Wren Therapeutics Limited - All Rights Reserved